Razzouk B I, Srinivas S, Sample C E, Singh V, Sixbey J W
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN 38101-0318, USA.
J Infect Dis. 1996 Mar;173(3):529-35. doi: 10.1093/infdis/173.3.529.
Epstein-Barr virus (EBV) antigens in tumor tissue define associations of virus with human malignancies and provide clues as to mechanisms of viral oncogenesis. In Burkitt's lymphoma, EBV markers are absent from 85% of sporadic cases and 4% of endemic (African) cases, raising questions as to the exact role EBV in the disease. Standard screening criteria may be insufficient to determine the EBV status of all tumors. One of 9 tumors from American patients expressed EBV nuclear antigen 1 (EBNA1) and contained standard episomal EBV DNA, making this series consistent with the 15% EBV association traditionally ascribed to sporadic Burkitt's lymphoma. Surprisingly, 3 tumors without detectable EBNA1 contained partial EBV genomes. Identification of defective, integrated viral DNA in some tumors indicates greater involvement of virus in sporadic Burkitt's lymphoma than previously documented and suggests a process of viral DNA rearrangement and loss during malignant progression most consistent with an initiating role for EBV in tumorigenesis.
肿瘤组织中的爱泼斯坦-巴尔病毒（EBV）抗原确定了病毒与人类恶性肿瘤的关联，并为病毒致癌机制提供了线索。在伯基特淋巴瘤中，85%的散发性病例和4%的地方性（非洲）病例中不存在EBV标志物，这引发了关于EBV在该疾病中的确切作用的疑问。标准筛查标准可能不足以确定所有肿瘤的EBV状态。美国患者的9个肿瘤中有1个表达了EBV核抗原1（EBNA1）并含有标准的游离型EBV DNA，使得该系列与传统上归因于散发性伯基特淋巴瘤的15%的EBV关联一致。令人惊讶的是，3个未检测到EBNA1的肿瘤含有部分EBV基因组。在一些肿瘤中鉴定出有缺陷的整合病毒DNA表明，病毒在散发性伯基特淋巴瘤中的参与程度比以前记录的更高，并提示在恶性进展过程中病毒DNA重排和丢失的过程，这与EBV在肿瘤发生中的起始作用最为一致。
